

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

GID- MT553 Synergo for non-muscle-invasive bladder cancer

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

Synergo is contraindicated in pregnancy. Pregnancy is a protected characteristic under the Equality Act 2010.

Bladder cancer is more common in men than in women, and most cases happen in people aged 60 and over. Women diagnosed with bladder cancer are more likely to present at an advanced stage and have worse prognosis and outcomes than men. Bladder cancer is more common in white people than in black or Asian people. Age, sex and race are protected characteristics under the Equality Act. People with cancer are considered to have a disability under the Equality Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee should consider the impact that some of the above equality considerations may have on access to Synergo for people with protected characteristics.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No. The information above was included as a special consideration.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director: Chris Chesters (acting AD)

Date: 11/02/2021